The Efficacy and Safety of Quetiapine XR in Patients With Schizophrenia Switched From Other Antipsychotics
Status:
Completed
Trial end date:
2012-03-01
Target enrollment:
Participant gender:
Summary
Purpose To evaluate the efficacy and safety of once-daily quetiapine extended release (XR) in
patients with schizophrenia switched from other antipsychotics which were suboptimal due to
insufficient efficacy or insufficient tolerability.
Methods:
This was a 12-week, open-label study conducted in the Chinese population in Taiwan.
Quetiapine XR was administrated at 300 mg on day 1, 600 mg on day 2 and up to 800 mg after
day 2. From day 8 until the end of the study, the dose of quetiapine XR was adjusted within
400-800 mg per day, depending on the clinical response and tolerability of the patients.